



SEQUENCE LISTING

<110> Variation Biotechnologies, Inc.  
Torres, Jose Vidal

<120> IMMUNOGENIC FORMULATION AND PROCESS FOR PREPARATION THEREOF

<130> 3648.032

<160> 16

<170> PatentIn version 3.3

<210> 1

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 1

Cys Thr Asp Leu Lys Asn Ala Thr Asn Thr Asn Ser Ser Ser Ser Arg  
1 5 10 15

Met Met Met Glu Lys  
20

<210> 2

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 2

Phe Tyr Lys Leu Asp Ile Val Pro Ile Asp Asn Thr Thr Ser Ser Tyr  
1 5 10 15

Arg Leu Ile Asn Cys  
20

<210> 3

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 3

Thr Ser Lys Ser Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr  
1 5 10 15

Gly Asp Ile Gly Asp  
20

<210> 4

<211> 21

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 4

Phe Asn Ser Thr Trp Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser Asn  
1 5 10 15

Asn Thr Glu Gly Ser  
20

<210> 5  
<211> 20  
<212> PRT  
<213> Human immunodeficiency virus type 1

<400> 5

Thr Arg Asp Gly Gly Asn Asn Asn Asn Glu Thr Glu Ile Phe Arg Pro  
1 5 10 15

Gly Gly Gly Asp  
20

<210> 6  
<211> 24  
<212> PRT  
<213> Hepatitis C virus

<400> 6

Ala Thr Thr Tyr Val Thr Gly Gly Ala Ala Ala Arg Ala Thr Ala Gly  
1 5 10 15

Leu Ala Ser Leu Phe Ser Pro Gly  
20

<210> 7  
<211> 14  
<212> PRT  
<213> Hepatitis C virus

<400> 7

Ile Ser Tyr Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro Tyr  
1 5 10

<210> 8  
<211> 21  
<212> PRT  
<213> Influenza A virus

<400> 8

Glu Thr Gly Lys Arg Gly Gly Lys Ser Ser Gly Ser Ser Tyr Pro Val  
1 5 10 15

Leu Asn Val Ser Tyr  
20

<210> 9  
<211> 21  
<212> PRT  
<213> Influenza A virus

<400> 9

Lys Lys Gly Ser Val His His Pro Ser Thr Ile Thr Glu Gln Thr Ser  
1 5 10 15

Leu Tyr Val Asn Ala  
20

<210> 10  
<211> 21  
<212> PRT  
<213> Influenza A virus

<400> 10

Asn Gly Leu Phe Ser Lys Glu Ser Pro Asn Asn Lys Asn Lys Asp Pro  
1 5 10 15

Ile Asp Thr Cys Asp  
20

<210> 11  
<211> 21  
<212> PRT  
<213> Influenza A virus

<400> 11

Tyr Val Ser Val Ser Ser Ser Arg Ile Ala Ser Arg Pro Lys Val Arg  
1 5 10 15

Gly Gln Gly Asp Thr  
20

<210> 12  
<211> 28  
<212> PRT  
<213> Human immunodeficiency virus type 1

<400> 12

Cys Thr Asn Val Asn Thr Asn Asn Thr Thr Asn Thr Thr Ser Ser Ser  
1 5 10 15

Gly Gly Thr Met Glu Lys Gly Glu Met Lys Asn Cys  
20 25

<210> 13  
<211> 30  
<212> PRT

<213> Human immunodeficiency virus type 1

<400> 13

Met Thr Thr Glu Leu Arg Asp Lys Lys Gln Lys Glu Tyr Ala Leu Phe  
1 5 10 15

Tyr Arg Leu Asp Val Val Pro Ile Asp Asn Asn Ser Thr Ser  
20 25 30

<210> 14

<211> 27

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 14

Arg Lys Ser Ile Arg Ile Gly Pro Gly Gln Ala Phe Tyr Ala Thr Gly  
1 5 10 15

Asp Ile Ile Gly Asp Ile Arg Gln Ala His Cys  
20 25

<210> 15

<211> 24

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 15

Cys Asn Ser Thr Gln Leu Phe Asn Ser Thr Trp Ser Thr Glu Gly Ser  
1 5 10 15

Asn Asn Thr Glu Gly Ser Asp Thr  
20

<210> 16

<211> 15

<212> PRT

<213> Human immunodeficiency virus type 1

<400> 16

Gly Asn Asn Asn Ser Ser Asn Glu Ile Phe Arg Pro Gly Gly Gly  
1 5 10 15